Tech & Science: Ebola hasn't been cured yet, but two experimental drugs are showing significant progress - PressFrom - United Kingdom
  •   
  •   

Tech & ScienceEbola hasn't been cured yet, but two experimental drugs are showing significant progress

17:10  14 august  2019
17:10  14 august  2019 Source:   popsci.com

Ebola Funds Won't Help Congo Until the Disease Spreads

Ebola Funds Won't Help Congo Until the Disease Spreads The World Bank's bid to aid countries battling Ebola is contingent on some strict conditions.

Two experimental treatments significantly improve survival rates from Ebola , according to preliminary data reported this week from a clinical trial testing the drug in the Democratic Republic of Congo, where an Ebola outbreak is ongoing. We should be optimistic, but not overstate.”

In a development that transforms the fight against Ebola , two experimental treatments are working so well that they will now be offered to all patients in the Democratic Republic of Congo, scientists announced on Monday.

Ebola hasn't been cured yet, but two experimental drugs are showing significant progress © Sean Hawkey Billo Mamadou Diallo, Karamoko Sonah Camara, Alain Mukendi, Jean Francoi Tolno and Hawa Madi, part of Team Nine of the WHO Ebola vaccine trial staff, at work in Katongourou, Guinea . The World Health Organisation is running phase III clinical trials for Ebola virus disease vaccine in Guinea. The technique being used is "ring vaccination" which was used in the 1970s to eradicate smallpox.

Two experimental treatments significantly improve survival rates from Ebola, according to preliminary data reported this week from a clinical trial testing the drug in the Democratic Republic of Congo, where an Ebola outbreak is ongoing.

Dikembe Mutombo sends Ebola message to Congo amid outbreak

Dikembe Mutombo sends Ebola message to Congo amid outbreak Mutombo, who was born in the Congo, said the Congolese people need to hear the safety messages from someone who they can trust.

Two experimental Ebola drugs under review in the Democratic Republic of Congo already seem to be saving the lives of many affected by the deadly virus The two drugs — one developed by Regeneron Pharmaceuticals and the other by researchers with the US National Institutes of Health, which helped

My WebSummit keynote keeps echoing through stories calling for an end to #HustlePorn "What I hope is that more and more founders that go on this journey realize that their physical health and mental Ebola hasn ' t been cured yet , but two experimental drugs are showing significant progress .

If patients received either of the two drugs early in their disease progression, risk of death dropped to around 10 percent. Overall, only around 30 percent of the patients taking the two drugs died. The fatality rate for the ongoing outbreak with the standard care is around 67 percent.

The findings represent a significant step forward, says Jason Kindrachuk, an Ebola researcher and assistant professor of viral pathogenesis in the department of medical microbiology at the University of Manitoba in Canada. “In the last outbreak, we didn’t really have anything in our arsenal we felt confident in. This is a major breakthrough.”

In pictures: Democratic Republic of Congo races to contain Ebola (Reuters)

In addition, that researchers were able to conduct a well-designed trial in the midst of a disease outbreak was its own success. During the 2014 Ebola outbreak, the scientific community struggled to identify the best, most ethically sound way to use—and collect data on—experimental drugs. In the aftermath, the World Health Organization developed a framework called the Monitored Emergency Use of Unregistered Interventions, which set out criteria for experimental drug use during active outbreaks. This trial was the first to put this protocol into practice.

Here’s why Ebola has been so hard to contain in Eastern Congo

Here’s why Ebola has been so hard to contain in Eastern Congo Levels of citizens' mistrust shape how they respond to the epidemic. Less than a third of the study participants trusted that local authorities represent their interests (according to the study, citizen trust is even lower as you move up levels of governance). A quarter of the study participants believed that the Ebola outbreak was not real. Study participants with low institutional trust and belief in misinformation had a decreased likelihood of adopting behaviors that would prevent Ebola infection, including acceptance of Ebola vaccines.

Experimental drugs are experimental drugs because we don’ t know if they will work. That is true both with the preparations patients received in An ethics panel from WHO recently said that it is ethical to give out experimental treatments to Ebola patients, but it has not yet specified who should

International health officials say two experimental drugs used to treat Ebola infections appear to The group recommended that all new patients should receive either of the two drugs that showed the The drugs are antibodies that work by blocking the virus in the body. One drug , REGN-EB3, is

“It’s a proof of concept that this framework can be applied during an Ebola outbreak, and patients can be ethically treated while we collect data that can make a real difference in the future,” says Julie Fisher, associate research professor in the department of microbiology and member of the Center for Global Health Science and Security at Georgetown University Medical Center. “That we can do this in a way that is scientifically sound—that is a real step forward for research during outbreaks.”

The clinical trial compared three drugs to ZMapp, an experimental treatment that was introduced in the 2014 Ebola outbreak and seemed promising, but wasn’t proven to be effective due to limited data collection. An analysis of 499 patients found that two of the drugs—REGN-EB3 (developed by Regeneron Pharmaceuticals) and mAb114 (developed by the National Institute of Allergy and Infectious Diseases)—improved survival rates more than ZMapp and a fourth drug. The clinical trial will continue with REGN-EB3 and mAb114, and the other two drugs will be dropped.

Congo confirms 1st Ebola case in city of Goma

Congo confirms 1st Ebola case in city of Goma BENI, Congo (AP) — The Congolese health ministry confirmed an Ebola case in Goma late Sunday, marking the first time the virus has reached the city of more than 2 million people along the border with Rwanda since the epidemic began nearly a year ago. 

Ebola hasn ' t been cured yet , but two experimental drugs are showing significant progress .

On Tuesday, two people cured of Ebola using the experimental drugs were released from a treatment centre in Goma, eastern DR Congo, and reunited with their families. Two other treatments, called ZMapp and Remdesivir, have been dropped from trials as they were found to be less effective.

Read more: The second-deadliest Ebola outbreak is killing mostly women (ELLE UK)

Both successful drugs are antibody treatments, which means they bind to a particular protein on the surface of the Ebola virus and prevent it from infecting cells in the body. “I think what we’re seeing is that these neutralizing antibodies work quite well,” Kindrachuk says.

However, there are important caveats to the successful results seen in the trial. “It’s premature to say that this is a curative treatment,” Fisher says. “We should be optimistic, but not overstate.”

Both drugs were most effective in situations where patients came to the clinic early on in their disease, and who had low levels of the virus in their blood. But medical staff working in outbreak areas have found it difficult to get people into clinics that quickly. Lack of knowledge about the disease and low trust in medical professionals is still a significant barrier. “When I was back in Sierra Leone about a month ago, people were asking how to prove that Ebola is real,” Kindrachuk says. “That’s the perspective we’re still dealing with.”

This doctor survived Ebola. Now, he treats other sufferers

This doctor survived Ebola. Now, he treats other sufferers Every time a doctor enters the treatment area at the Ebola medical centre in Beni, the support staff write their name on the section of their protective suits which covers their foreheads. It is something of a necessity for it can be difficult to distinguish each medic under their masks and multiple layers of biohazard gear. However, Dr Kambale Philemon does not need his name inked on his suit because everybody knows who he is. © Other Dr Philemon says as a survivor of Ebola, he understands what his patients go through The 46-year old is an Ebola survivor.

Ebola hasn ' t been cured yet , but two experimental drugs are showing significant progress .

The experimental drugs will be made widely available in the centers that have already treated thousands of patients. “We now have seen that there are at least two therapies that are showing a beneficial effect in prolonging the life or decreasing the mortality of Ebola virus disease,” said Dr

Watch: The team behind the Ebola vaccination breakthrough (France 24)

Most people do not show up to clinics with low levels of the virus, Fisher says. While the results of the trial are good news, she says, rolling the drug out has to be coupled with improved disease surveillance and community trust. “We need to be able to have people cooperate with health authorities, and trust that they can report at the first signs of disease for screening and treatment,” she says. “Combined with that, the drugs are promising tools. Without any other changes, they’re not going to stop the epidemic by themselves.”

Researchers will have to follow patients who are treated with the new drugs, as well. It's still not clear if the Ebola virus persists in hidden parts of patients' bodies, even after they look healthy, Kindrachuk says. In Ebola survivors, the virus can linger in the testes, central nervous system, and eyes long after it is gone from the rest of the body. "These are pressing questions," he says, and probably need to be addressed through tests around the treatment delivery method and timing. Those questions are hard to answer, though, because bringing patients back in for follow-up tests and sample collection is challenging in developing countries. "We'll probably have to rely more on animal data," he says.

Can the 'Ebola Hunter' Keep This Outbreak From Going Worldwide?

Can the 'Ebola Hunter' Keep This Outbreak From Going Worldwide? Can the 'Ebola Hunter' Keep This Outbreak From Going Worldwide?

An experimental Ebola drug called ZMapp was given to two Americans infected with Ebola . The Americans are improving after being given the Ebola drug .

It’s clear to me now that the correct decision for @WebSummit is to rescind Marine Le Pen’s invitation. Ebola hasn ' t been cured yet , but two experimental drugs are showing significant progress .

Kindrachuk also stresses that having a promising drug does not mean Ebola deserves any less attention, or that there shouldn’t be investment in aid. “My concern is always if the response will be to take away from public interest in creating healthcare infrastructure,” he says. “These drugs have a massive benefit, but we’re still reliant on proper infrastructure to supply them to people.”

Slideshow: Twenty-two habits to steal from people who never get sick (The Active Times)

Explore the issues faced by the UK’s most vulnerable children and young people this summer and discover what you can do to help.

Google search isn’t showing new content due to indexing issues.
The issues have lasted for more than 12 hours

—   Share news in the SOC. Networks

Topical videos:

usr: 1
This is interesting!